VC23 Ventures
Investing in
Life Science & Beyond
Backing the companies shaping
the next 20 years of biology
WE DONT JUST INVEST IN BIOTECH—WE HELP MAKE IT SMARTER
A collaborative venture investment platform for biotech innovation
VC23 helps visionary entrepreneurs turn bold discoveries into enduring value
What sets us apart?
We use proprietary analytics and AI-enhanced diligence to evaluate scientific, financial, and market data with greater depth and speed—helping uncover value others might miss.
BioTools Focus
VC23 invests across all sectors, but our focus is BioTools because they generally scale faster and more efficiently than therapeutics, they typically reach revenue and partnerships earlier than many other biotech sectors, and they often require less capital before exit. We also believe that the Biotool sector will continue to attract steady acquisition interest from global incumbents.
Commitment
Every investment VC23 presents is backed by deep technical and commercial diligence. We also apply the same rigor to investor communications: Our investor portal generates tailored updates for all portfolio companies, including performance summaries, and news alerts. Our commitment is to keep investors informed, aligned, and in control.
Why Now?
The convergence of compute, AI, and biology isn’t just additive—it’s multiplicative. Each discovery accelerates the next, creating a feedback loop for innovation. Faster drug discovery, scalable synthetic biology, and precision diagnostics at unprecedented speed and scale are possible—it’s already happening. AI and digitization are driving new engines of experimentation.
$280B
Estimated global life-science tools market value by 2030, growing at a CAGR of 10–11%, driven by cell- and gene-therapy, proteomics, and synthetic-biology demand, and expanding academic–industry collaboration worldwide.
70%+
Portion of large biopharma R&D budgets now directed toward externalized research tools and services, up from ~50 % a decade ago, driven by the rise of CROs, cloud biology, and AI-enabled lab automation.
$1.3T
Biopharma companies have approximately $1.3 trillion in potential capital available for M&A, supported by strong balance sheets and debt-raising capacity. U.S. private equity healthcare deal value grew 19% year-over-year (KPMG, 2025)